GE HealthCare posts strong Q3 2026 results and lifts FY2026 outlook
GE HealthCare reported third‑quarter 2026 revenue of $5.51 billion, up 7.2% year‑over‑year, and adjusted earnings per share of $1.34, a 25.1% increase. Net income margin expanded to 11.1% and free cash flow rose to $793 million. The company raised its full‑year 2026 adjusted EPS guidance to $4.95‑$5.05 and adjusted EBIT‑margin outlook to 15.5%‑15.7%, and announced a pending acquisition of SOFIE Biosciences for $945 million.
Why it matters
The higher EPS guidance signals stronger profitability expectations for FY2026, which could lift the valuation of GEHC shares (the company said the new range reflects the recent margin expansion). The $945 million SOFIE acquisition adds U.S. PET radiopharmaceutical capability, potentially expanding future revenue streams.
Key facts
- 1Q3 2026 revenue was $5.51 billion, up 7.2% YoY. stocktitan.net
- 2Adjusted EPS for the quarter was $1.34, a 25.1% YoY increase. zacks.com
- 3GAAP EPS was $1.36, up 39.1% YoY. stocktitan.net
- 4Free cash flow for the quarter was $793 million, up $310 million YoY. investing.com
- 5Backlog reached $23.7 billion. stocktitan.net
- 6Full‑year 2026 adjusted EPS guidance was raised to $4.95‑$5.05. investing.com
Summary written by AlphAI AI Desk from 20 of 32 sources. Not investment advice. Figures are as stated by the linked sources.